Bio Green Med Solution, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
BGMS$0.83-3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In $000s)
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Net loss | $(988) | $(1,957) | $(2,387) | $(8,160) |
| Translation adjustment | — | (14,586) | 3,271 | (12,967) |
| Unrealized foreign exchange gain (loss) on intercompany loans | — | 14,468 | (2,380) | 12,842 |
| Comprehensive loss | $(988) | $(2,075) | $(1,496) | $(8,285) |
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(In $000s, except share amounts)
| Preferred Stock · Common Stock · Additional Paid-in · Other Comprehensive · Accumulated · Total Stockholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | (Deficit) | |
| Balances at December 31, 2023 | 454,537 | $— | 4,412 | $— | $429,797 | $(908) | $(428,282) | $607 |
| Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering | — | — | 915 | — | (80) | — | — | (80) |
| Series B Preferred stock conversions | (119,000) | — | 165 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 203 | — | — | 203 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | (2,130) | — | (2,130) |
| Translation adjustment | — | — | — | — | — | 2,140 | — | 2,140 |
| Loss for the period | — | — | — | — | — | — | (2,946) | (2,946) |
| Balances at March 31, 2024 | 335,537 | $— | 5,493 | $— | $429,920 | $(898) | $(431,228) | $(2,206) |
| Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses | — | — | 2,029 | — | 6,290 | — | — | 6,290 |
| Stock-based compensation | — | — | — | — | 189 | — | — | 189 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | 504 | — | 504 |
| Translation adjustment | — | — | — | — | — | (521) | — | (521) |
| Loss for the period | — | — | — | — | — | — | (3,257) | (3,257) |
| Balances at June 30, 2024 | 335,537 | $— | 7,522 | $— | $436,399 | $(915) | $(434,485) | $999 |
| Expenses related to Securities Purchase Agreement In Private Placement | — | — | — | — | (1) | — | — | (1) |
| Exercise of pre-funded warrants | — | — | 1,446 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 107 | — | — | 107 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | 14,468 | — | 14,468 |
| Translation adjustment | — | — | — | — | — | (14,586) | — | (14,586) |
| Loss for the period | — | — | — | — | — | — | (1,957) | (1,957) |
| Balances at September 30, 2024 | 335,537 | $— | 8,968 | $— | $436,505 | $(1,033) | $(436,442) | $(970) |
| Balances at December 31, 2024 | 135,537 | $— | 36,913 | $— | $438,211 | $(891) | $(439,494) | $(2,174) |
| Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses | — | — | — | — | (248) | — | — | (248) |
| Exercise of Pre-Funded Warrants | — | — | 15,277 | — | — | — | — | — |
| Issue of common stock on Securities Purchase Agreement | — | — | 758 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 1,666 | — | — | 1,666 |
| Issue of Series C preferred stock in Securities Purchase Agreement | 1,000,000 | 1 | — | — | 999 | — | — | 1,000 |
| Series C Preferred stock conversions | (1,000,000) | (1) | 11,042 | — | 1 | — | — | — |
| Issue of Series D preferred stock in Securities Purchase Agreement | 2,100,000 | 2 | — | — | 1,892 | — | — | 1,894 |
| Series D Preferred stock conversions | (1,745,262) | (2) | 799,912 | 1 | 1 | — | — | — |
| Issue of Series E preferred stock in Securities Purchase Agreement | 1,000,000 | 1 | — | — | 999 | — | — | 1,000 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | (2,380) | — | (2,380) |
| Translation adjustment | — | — | — | — | — | 2,385 | — | 2,385 |
| Deconsolidation of wholly-owned foreign operation | — | — | — | — | — | 886 | (886) | — |
| Loss for the period | — | — | — | — | — | — | (81) | (81) |
| Balances at March 31, 2025 | 1,490,275 | $1 | 863,902 | $1 | $443,521 | $— | $(440,461) | $3,062 |
| Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses | — | — | 940 | — | — | — | — | — |
| Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses | — | — | — | — | 20 | — | — | 20 |
| Issue of Series F preferred stock in Securities Purchase Agreement | 3,000,000 | 3 | — | — | 2,997 | — | — | 3,000 |
| Series D Preferred stock conversions | (354,738) | — | 162,588 | — | — | — | — | — |
| Series E Preferred stock conversions | (1,000,000) | (1) | 458,333 | 1 | — | — | — | — |
| Exercise of Warrants | — | — | 98,202 | — | — | — | — | — |
| Payment made under the Warrant Exchange Amendment | — | — | — | — | (1,100) | — | — | (1,100) |
| Stock-based compensation | — | — | — | — | 7 | — | — | 7 |
| Preferred stock dividends | — | — | — | — | (41) | — | — | (41) |
| Loss for the period | — | — | — | — | — | — | (1,318) | (1,318) |
| Balances at June 30, 2025 | 3,135,537 | $3 | 1,583,965 | $2 | $445,405 | $— | $(441,779) | $3,631 |
| Issue of common stock on share exchange agreement to purchase Fitters Sdn. Bhd | — | — | 699,158 | 1 | 4,449 | — | — | 4,450 |
| Series F Preferred stock conversions | (3,000,000) | (3) | 654,000 | — | — | — | (3) | |
| Warrant Exchange | — | — | 559,395 | — | 1,494 | — | (1,494) | — |
| Stock Split Adj | — | — | 1,019 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 6 | — | — | 6 |
| Loss for the period | — | — | — | — | — | — | (988) | (988) |
| Balances at September 30, 2025 | 135,537 | $— | 3,497,537 | $3 | $451,354 | $— | $(444,261) | $7,096 |
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In $000s)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(2,387) | $(8,160) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1 | 5 |
| Stock-based compensation | 1,679 | 499 |
| Gain on deconsolidation of subsidiary | 4,947 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (725) | — |
| Inventory | (1,368) | — |
| Prepaid expenses and other assets | 1,855 | 3,129 |
| Lease liability | 5 | (37) |
| Accounts payable, accrued and other current liabilities | (8,744) | (2,070) |
| Net cash used in operating activities | (4,737) | (6,634) |
| Investing activities: | ||
| Net cash used in investing activities | — | — |
| Financing activities: | ||
| Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net | 5,564 | 6,209 |
| Payment of preferred stock dividend | (41) | — |
| Net cash provided by financing activities | 5,523 | 6,209 |
| Effect of exchange rate changes on cash and cash equivalents | (85) | 29 |
| Net increase (decrease) in cash and cash equivalents | 701 | (396) |
| Cash and cash equivalents, beginning of period | 3,137 | 3,378 |
| Cash and cash equivalents, end of period | $3,838 | $2,982 |
| Supplemental cash flow information: | ||
| Non cash financing activities: | ||
| Issuance of shares in acquisition of Fitters Sdn. Bhd. | $4,450 | $— |
| Warrant Exchange | $4,212 | $— |
| Cash received during the period for: | ||
| Interest | $22 | $59 |
| Research & development tax credits | $— | $3,715 |
| Cash paid during the period for: | ||
| Interest | 6 | — |
| Taxes | $— | $2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.